pr-bio

Clostridium Botulinum Toxin type A

2017 IND submission, 2018 NDA(Export only)(expected)

2019 Clinical study Phase I, 2020 Clinical study Phase III

2021 Registration in Korea
Indication study

Expanding indications including dynamic equinus foot deformity, upper limb spasticity and blepharospasm etc.
Formulation study

Developing new formulation to improve stability and compliance
Modified Botulinum Toxin study

Developing advanced botulinum toxin
Health supplement for Inner-beauty

Developing health supplement for inner-beauty using marine bio extract

Government(Ministry of Oceans and Fisheries)-funded R&D project